ArticleDigestive diseases and sciences2022

Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.

Baldeep S Pabla et al.PubMed ↗Publisher ↗

No numbers read from the abstract.